Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on December 19, 2016. The report addresses a material event occurring subsequent to the company's underwritten public offering that closed on November 29, 2016.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on capital structure changes regarding share counts.
Material Changes
- Share Conversion: Between November 29, 2016, and December 16, 2016, 40 shares of Series A convertible preferred stock were converted into 2,666,680 shares of common stock.
- Outstanding Shares: As of December 16, 2016, the total number of common stock shares outstanding was 9,634,988.
- Regulatory Filing: The company filed a report with the Nasdaq Capital Market on December 19, 2016, to satisfy continued listing requirements based on the updated share count.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or contingencies beyond the specific event of share conversion and the resulting update to Nasdaq.
Key Facts for Investor Verification
- Verify the total number of common shares outstanding (9,634,988) as of December 16, 2016.
- Confirm the conversion ratio and terms of the Series A preferred stock that resulted in the issuance of 2,666,680 common shares.
- Review the impact of the November 29, 2016 public offering on the company's current capitalization.